LYRM03 是一种可从 Streptomyces HCCB10043 中分离得到的 Ubenimex (MS-N23909) 衍生物和 Aminopeptidase N 抑制剂,可抑制 TLR4、MyD88、NLRP3、ASC、NF-κB、p38 MAPK,稳定 IκB,并抑制 LPS 诱导的 iNOS 及 COX-2 表达,同时可降低炎症细胞因子和氧化应激标志物水平、减轻肺水肿,具有抗炎活性以及对乳腺癌的抗癌活性,可用于急性肺损伤和乳腺癌的研究。
产品编号: MS-Z08627 CAS No.: 1820750-36-4 分子式: C21H33N3O5 分子量: 407.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

LYRM03 是一种可从 Streptomyces HCCB10043 中分离得到的 Ubenimex (MS-N23909) 衍生物和 Aminopeptidase N 抑制剂,可抑制 TLR4、MyD88、NLRP3、ASC、NF-κB、p38 MAPK,稳定 IκB,并抑制 LPS 诱导的 iNOS 及 COX-2 表达,同时可降低炎症细胞因子和氧化应激标志物水平、减轻肺水肿,具有抗炎活性以及对乳腺癌的抗癌活性,可用于急性肺损伤和乳腺癌的研究。

生物实验数据

生物活性 LYRM03 is a Ubenimex (MS-N23909) derivative and Aminopeptidase N inhibitor that can be isolated from Streptomyces HCCB10043; it inhibits TLR4, MyD88, NLRP3, ASC, NF-κB, and p38 MAPK, stabilizes IκB, suppresses LPS-induced iNOS and COX-2 expression, reduces inflammatory cytokines and oxidative stress markers, and alleviates pulmonary edema, exhibiting anti-inflammatory activity and anticancer activity against breast cancer, and can be used for research on acute lung injury and breast cancer.
IC50 & Target

COX-2

 

iNOS

 

TLR4

 

NLRP3

 

Microbial Metabolite

 

体外研究
(In Vitro)

LYRM03 (50-200 μM; 6-24 h) 孵育 6、12 或 24 小时后,对 NR8383 大鼠肺泡巨噬细胞的活力无影响。
LYRM03 (50-200 μM; 24 h) 可呈剂量依赖性降低 LPS 诱导的 NR8383 大鼠肺泡巨噬细胞培养上清中 TNF-α、IL-1β 和 IL-18 水平的升高 (孵育 24 小时后)。
LYRM03 (50-200 μM; 24 h) 呈剂量依赖性抑制脂多糖 (LPS) 诱导的 NR8383 大鼠肺泡巨噬细胞中 NF-κB/TLR4/MyD88 信号通路的激活。
LYRM03 (50-200 μM; 24 h) 呈剂量依赖性抑制脂多糖 (LPS) 诱导的 NR8383 大鼠肺泡巨噬细胞中 NLRP3 炎症小体的上调。
LYRM03 (50-500 µmol/L; 1 h pre-incubation + 2 h, 4 h, 16 h, 24 h LPS treatment) 可抑制脂多糖 (LPS) 诱导的小鼠肺泡巨噬细胞中炎症介质的表达及一氧化氮生成,在 50 至 500 µmol/L 的浓度范围内可呈剂量依赖性抑制 iNOS、COX-2 和 Myd88 的表达。
LYRM03 (100 µmol/L; 1 h pre-incubation + 5-60 min LPS stimulation) 可通过抑制 LPS 诱导的 IκB 降解和 p38 MAPK 磷酸化,在 100 µmol/L 浓度下抑制小鼠肺泡巨噬细胞中依赖 Myd88 的 TLR4 信号通路。
LYRM03 (10-100 μg/mL; 1 h) 在 50 μg/mL 和 100 μg/mL 浓度下可将乳腺癌 MDA-MB-231 细胞中的 APN 酶活性抑制 50% 以上,且不会改变 APN 蛋白表达。
LYRM03 (10-100 μg/mL; 6-48 h) 在浓度高达 100 μg/mL、孵育时间长达 48 h 的条件下,诱导乳腺癌 MDA-MB-231 细胞的死亡率低于 20%。
LYRM03 (10-100 μg/mL; 6-48 h) 在浓度高达 100 μg/mL、孵育时间长达 48 h 的条件下,不会诱导乳腺癌 MDA-MB-231 细胞发生显著凋亡。
LYRM03 (10-100 μg/mL; 6-24 h) 可在伤口愈合实验中剂量依赖性地抑制乳腺癌 MDA-MB-231 细胞的迁移,其中以 100 μg/mL 作用 24 h 的效果最强。
LYRM03 (50-100 μg/mL; 10 days) 可在 50 μg/mL 和 100 μg/mL 浓度下作用 10 天,减少乳腺癌 MDA-MB-231 细胞的集落形成。

Cell Viability Assay

Cell Line: NR8383 rat alveolar macrophage cell line
Concentration: 50 μM; 100 μM; 200 μM
Incubation Time: 6 h; 12 h; 24 h
Result: Showed no significant alteration in cell viability in any group treated with LYRM03, with or without LPS stimulation, relative to the Sham group (p > 0.05).

ELISA Assay

Cell Line: NR8383 rat alveolar macrophage cell line
Concentration: 50 μM; 100 μM; 200 μM
Incubation Time: 24 h after LPS stimulation
Result: Reduced LPS-induced elevated levels of TNF-α, IL-1β, and IL-18 in cell supernatants relative to the LPS-only group (p < 0.05).
Exhibited no effect on cytokine levels when used alone.

Western Blot Analysis

Cell Line: murine alveolar macrophages
Concentration: 100 µmol/L (pre-incubation for 1 h, LPS stimulation for 5, 15, 30, 45, 60 min)
Incubation Time: 1 h pre-incubation + 5, 15, 30, 45, 60 min LPS stimulation
Result: Significantly reduced LPS-induced IκB degradation at 15, 30, and 45 min post-LPS stimulation.
Significantly inhibited LPS-induced p38 MAPK phosphorylation at 15, 30, 45, and 60 min post-LPS stimulation, while total p38 protein levels remained unchanged.

Apoptosis Analysis

Cell Line: MDA-MB-231
Concentration: 10 μg/mL; 50 μg/mL; 100 μg/mL
Incubation Time: 6 h; 12 h; 24 h; 48 h
Result: Detected no significant cleaved PARP expression via western blot.
Showed no significant increase in apoptotic cells in any treated group compared to untreated controls via flow cytometry.
体内研究
(In Vivo)

LYRM03 (腹腔注射;LPS 暴露后 1 h 和 12 h 给予;5-20 mg/kg) 可呈剂量依赖性地对大鼠 LPS 诱导的急性肺损伤发挥保护作用,其中 20 mg/kg 剂量对肺损伤评分、炎症标志物、氧化应激及 NF-κB/TLR4/NLRP3 通路激活的抑制作用最为显著。
LYRM03 (20 mg/kg;腹腔注射;单次) 对健康大鼠的肺损伤、氧化应激、炎症反应或 NF-κB/TLR4/NLRP3 通路活性均无显著影响。
LYRM03 (腹腔注射,10 mg/kg) 可有效缓解雄性 C57BL/6 小鼠中 LPS 诱导的急性肺损伤,通过抑制 Myd88 依赖的 TLR4 信号通路减少炎症细胞浸润、促炎细胞因子产生及肺组织损伤。
LYRM03 (腹腔注射;于 LPS 给予后 1 h 和 12 h 给予,剂量为 5-20 mg/kg) 可呈剂量依赖性地保护大鼠免受 LPS 诱导的急性肺损伤,其中 20 mg/kg 剂量的作用最强,可通过抑制 NF-κB/MyD88/TLR4 轴、减轻氧化应激、炎症反应及肺细胞凋亡发挥作用。
LYRM03 (100 mg/kg;腹腔注射;每周 3 次) 可在 MDA-MB-231 乳腺癌 SCID 小鼠模型中强效减少肺转移灶的形成。

Animal Model: Sprague-Dawley rats (220-250 g; LPS-induced acute lung injury)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.p.; at 1 and 12 h after LPS exposure
Result: Reduced LPS-induced lung injury scores, lung wet/dry weight ratio, and protein content in BALF in a dose-dependent manner.
Decreased LPS-induced increases in myeloperoxidase (MPO) activity in lung tissue, serum malondialdehyde (MDA) levels, and serum levels of TNF-α, IL-1β, and IL-18 in a dose-dependent manner.
Increased serum superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels in a dose-dependent manner.
Inhibited LPS-induced upregulation of TLR4, MyD88, p-IKKα, p-IKKβ, p-IκBα, p-NF-κB protein and mRNA levels, as well as NLRP3, ASC, and caspase-1 protein and mRNA levels in lung tissue in a dose-dependent manner.
Increased lung injury scores when administered at 20 mg/kg alongside siRNA targeting NF-κB p65, TLR4, or NLRP3 compared to rats treated with 20 mg/kg LYRM03 plus LPS alone.
Animal Model: Sprague-Dawley rats (220-250 g; healthy)
Dosage: 20 mg/kg
Administration: i.p.; single administration
Result: Did not alter lung injury scores, lung wet/dry weight ratio, BALF protein content, lung MPO activity, serum MDA, SOD, or GSH-Px levels, or serum TNF-α, IL-1β, or IL-18 levels compared to sham-treated rats.
Did not affect TLR4, MyD88, NF-κB pathway components, or NLRP3 inflammasome protein and mRNA levels in lung tissue.
Animal Model: C57BL/6 (male, 6-12 weeks old, 22 g, Specific Pathogen-Free, intratracheal LPS-induced ALI)
Dosage: 10 mg/kg
Administration: i.p.; single dose (4-h groups); two doses, at time of LPS challenge and 12 hours post-challenge (24-h groups)
Result: Reduced LPS-induced BALF total protein concentration by approximately 32.7% at 4 hours.
Significantly reduced BALF total protein concentration at 24 hours.
Significantly decreased LPS-induced myeloperoxidase (MPO) activity in lung tissue at both 4 and 24 hours.
Attenuated LPS-induced inflammatory cell infiltration and inter-alveolar septal thickening in lung tissue at 4 and 24 hours.
Reduced LPS-induced mRNA expression of TNF-α, IL-1β, IL-6, and MIP-2 in lung tissue to approximately 30% of LPS-only levels at 4 hours.
Significantly decreased BALF concentrations of IL-6 and TNF-α at 4 hours.
Significantly suppressed LPS-induced iNOS and COX-2 protein expression in lung tissue at 24 hours.
Animal Model: Sprague-Dawley (adult male, 250-300 g, LPS-induced acute lung injury)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.p.; administered at 1 and 12 h after LPS
Result: Reduced lung injury score to 11.50, lung wet-dry weight ratio to 6.311, BALF protein to 75.37 mg/mL at 5 mg/kg.
Reduced lung injury score to 8.205, lung wet-dry weight ratio to 5.750, BALF protein to 61.81 mg/mL at 10 mg/kg.
Reduced lung injury score to 6.700, lung wet-dry weight ratio to 5.580, BALF protein to 52.55 mg/mL at 20 mg/kg.
Reduced BALF TNF-α to 222.6 pg/mL, IL-1β to 394.1 pg/mL, IL-6 to 403.4 pg/mL at 5 mg/kg.
Reduced BALF TNF-α to 129.6 pg/mL, IL-1β to 375.2 pg/mL, IL-6 to 274.1 pg/mL at 10 mg/kg.
Reduced BALF TNF-α to 93.84 pg/mL, IL-1β to 357.7 pg/mL, IL-6 to 271.5 pg/mL at 20 mg/kg.
Reduced pulmonary MPO activity to 0.3043 U/g, serum MDA to 63.33 nmol/mL, and increased serum SOD to 13.16 U/mL, serum GSH-Px to 132.5 U/mL at 5 mg/kg.
Reduced pulmonary MPO activity to 0.2749 U/g, serum MDA to 41.98 nmol/mL, and increased serum SOD to 15.46 U/mL, serum GSH-Px to 162.1 U/mL at 10 mg/kg.
Reduced pulmonary MPO activity to 0.2039 U/g, serum MDA to 30.12 nmol/mL, and increased serum SOD to 19.54 U/mL, serum GSH-Px to 198.8 U/mL at 20 mg/kg.
Reduced serum TNF-α to 90.79 pg/mL, IL-8 to 1125 pg/mL, IL-6 to 345.6 pg/mL at 5 mg/kg.
Reduced serum TNF-α to 58.95 pg/mL, IL-8 to 1040 pg/mL, IL-6 to 283.2 pg/mL at 10 mg/kg.
Reduced serum TNF-α to 53.43 pg/mL, IL-8 to 904.9 pg/mL, IL-6 to 161.5 pg/mL at 20 mg/kg.
Reduced lung protein levels of TLR4 to 2.255, NF-kB to 2.228, and increased IkB-α to 0.5054 at 5 mg/kg.
Reduced lung protein levels of TLR4 to 1.942, HMGB1 to 2.039, MyD88 to 1.775, NF-kB to 2.187, and increased IkB-α to 0.6831 at 10 mg/kg.
Reduced lung protein levels of TLR4 to 1.702, HMGB1 to 1.674, MyD88 to 1.441, NF-kB to 1.852, and increased IkB-α to 0.6996 at 20 mg/kg; corresponding mRNA expression of TLR4, HMGB1, MyD88, and NF-kB was also significantly reduced, while IkB-α mRNA was increased across all doses.
Reduced apoptotic index to 42.99%, Cleaved Caspase 3 protein to 5.544, BAX protein to 4.811, and increased Cleaved PARP protein to 0.5449, Bcl-2 protein to 0.6006 at 5 mg/kg.
Reduced apoptotic index to 33.51%, Cleaved Caspase 3 protein to 3.625, BAX protein to 4.247, and increased Cleaved PARP protein to 0.6978, Bcl-2 protein to 0.7134 at 10 mg/kg.
Reduced apoptotic index to 28.60%, Cleaved Caspase 3 protein to 2.496, BAX protein to 3.385, and increased Cleaved PARP protein to 0.8879, Bcl-2 protein to 0.7743 at 20 mg/kg.
Animal Model: SCID mice (female)
Dosage: 100 mg/kg
Administration: i.p.; 3 times per week
Result: Showed significantly fewer metastatic foci compared to control mice.
Demonstrated better inhibition of lung metastasis than bestatin.

化学信息

分子量 407.50
分子式 C21H33N3O5
CAS No. 1820750-36-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础